Referring patients to MoleMap takes the guesswork out of diagnosing skin cancer.
Our system combines proven skin-mapping technology and skin cancer expertise to spot melanoma early – when it's most treatable.
3 good reasons to refer patients to MoleMap
Early detection matters.
Early detection is key: patients diagnosed with a melanoma with a Breslow Thickness of <1mm have a five-year survival rate of between 92-96%, compared to 38.5-49.5% for those >4.0mm.2
What’s more, the economic and social burden of skin cancer in New Zealand is incredibly high, with an estimated annual cost of $123 million.1 Much of this cost would be avoidable with early diagnosis through a screening programme.
We check. And double-check.
Locating and diagnosing skin cancer within the length of a normal GP appointment can be high stress and high risk. Data from our Virtual Lesion Clinics shows that when patients present with one lesion of concern, there’s often another hiding in plain sight.3
MoleMap’s surveillance and diagnosis services give you and your patient piece of mind that lesions are double-checked and diagnosed by an expert Dermatologist.
Our service is impartial.
We don’t perform skin cancer surgery, so we return the patient to you, decreasing the number of benign lesions needing excision. MoleMap has an NNT (number needed to treat) of 4.8 for melanoma.4
Who should you refer? Any patients with suspicious or atypical moles or lesions, with 100+ moles, or with a family or personal history of melanoma (see what to look for).